Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $86.86 Average Price Target from Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $86.8571.

A number of equities research analysts have weighed in on the stock. Citigroup decreased their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. JPMorgan Chase & Co. raised their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. BTIG Research lifted their price objective on Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Mizuho upped their price objective on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $58.70 on Monday. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -33.74 and a beta of 1.08. The business has a 50-day simple moving average of $68.38 and a two-hundred day simple moving average of $62.44. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. During the same quarter last year, the firm posted ($1.19) EPS. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, analysts expect that Establishment Labs will post -2.41 earnings per share for the current year.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 33,925 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75. Following the transaction, the director owned 1,223,579 shares of the company’s stock, valued at approximately $73,891,935.81. This trade represents a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 11.09% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC grew its position in shares of Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after acquiring an additional 197,962 shares during the period. Bamco Inc. NY raised its holdings in Establishment Labs by 30.2% in the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after purchasing an additional 274,287 shares during the period. Tyro Capital Management LLC lifted its position in Establishment Labs by 1.0% during the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock valued at $44,165,000 after purchasing an additional 10,735 shares in the last quarter. William Blair Investment Management LLC lifted its position in Establishment Labs by 17.6% during the third quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock valued at $41,709,000 after purchasing an additional 152,299 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.